Researchers are using targeted protein degradation as a strategy to develop drugs that target disease-causing proteins where traditional inhibitor drugs can’t be used.
In this infographic, we discuss both inhibition and degradation, the advantages and challenges related to each approach, and the key points you need to consider when designing your protein degraders.
Ready to tackle your challenging affinity screening?
Discover tools you can use
37:25When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an
Use this downloadable list of 2023 Targeted Protein Degradation conferences to choose which one(s) to attend. Learn when and where they’ll happen, who’ll be there, and the main focus.
NanoTemper Technologies, announced today the launch of Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery....
Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...
Update: See which 2023 conferences you should watch for With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on...
With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...
35:47Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
56:52Are you working in the field of small molecule drug discovery? Join this webinar to explore the drug discovery workflow and discover tools that can help in your quest for the most promising lead com
59:35Bifunctional degrader molecules (aka PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases, forming a ternary complex that enables ubiquitination and degradation of the target
There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...
